Dose Insider / Analyses / GLP-1 stomach pain

Stomach Pain on a GLP-1What Is Common, What Is Not, and When to Worry

Updated November 20, 2026 路 17 min read 路 FDA labels 2026, NIDDK, MedlinePlus 2026

Abdominal pain is a common reaction to GLP-1 medicines and usually a mild one. In the label trials it was reported by 20% of adults on Wegovy 2.4 mg against 10% on placebo, and by 5% to 10% on Zepbound, Mounjaro and Ozempic against 4% to 5% on placebo.

20%of adults on Wegovy 2.4 mg reported abdominal pain in the label trials, against 10% on placebo
People reporting abdominal painLabel trials, share of participantsWEGOVY2.4 mg20%Placebo10%ZEPBOUND15 mg10%Placebo5%People reporting abdominalpainLabel trials, share of participantsWEGOVY2.4 mg20%Placebo10%ZEPBOUND15 mg10%Placebo5%

One in ten adults on placebo injections reported abdominal pain too.

On this page

Two rarer causes of pain are named in the warnings of all four labels: acute pancreatitis, whose sign is persistent or severe abdominal pain that sometimes spreads to the back, and gallbladder disease. The patient leaflets say to stop the medicine and call right away for severe pain that will not go away. Pain that is sudden and sharp, that does not improve in 24 to 48 hours, or that comes with fever, yellow skin or repeated vomiting also needs medical attention.1,2,5,9

How common abdominal pain is on each medicine

Each label has a table of the reactions reported in its placebo-controlled trials. These are the rows for abdominal pain.

MedicinePlaceboOn the drug, by weekly dose
Wegovy (semaglutide), 68-week trials10%2.4 mg20%
Wegovy, 72-week trials of the higher dose7%2.4 mg9%7.2 mg12%
Zepbound (tirzepatide)5%5 mg9%10 mg9%15 mg10%
Ozempic (semaglutide)4.6%0.5 mg7.3%1 mg5.7%
Mounjaro (tirzepatide)4%5 mg6%10 mg5%15 mg5%

Prescribing information for Wegovy, Zepbound, Ozempic and Mounjaro, section 6.1.1,2,3,4

Abdominal pain, by medicine and doseFDA labels
Medicine

The percentages count people who reported the reaction at least once, mild reports included. Compare each medicine with its own placebo group; the trials enrolled different people.

Three points help in reading these rows.

The row is a bundle. The Wegovy label notes that its row combines abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal tenderness, abdominal discomfort and epigastric discomfort. The Zepbound label combines a similar set.1,2 A person who reported mild discomfort after a large meal counts the same as one with real pain.

Half of it happens on placebo. One in ten adults on placebo injections reported abdominal pain in the Wegovy trials. The excess that can be put down to the drug is 10 points on Wegovy 2.4 mg, 4 to 5 points on Zepbound, 1 to 3 points on Ozempic and 1 to 2 points on Mounjaro.

The dose matters less than for nausea. On Zepbound the rate is level across the three doses, and on Ozempic and Mounjaro it was no higher on the top dose than on the lowest. Only the higher Wegovy dose shows a step, 12% on 7.2 mg against 9% on 2.4 mg in the same trials.1,2,3,4

What the usual pain is

The labels do not say what kind of pain people reported. Their neighbors in the same tables give a hint: dyspepsia, belching, abdominal distension, flatulence and reflux all appear as reactions more frequent on the drugs than on placebo.1,2,3 That is the cluster the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes as indigestion:7

The mechanism fits. All four labels state that the medicine delays the emptying of the stomach, and the joint nutrition advisory of four U.S. medical societies says that this delay leads to bloating, fullness and nausea.1,12 That would put the discomfort in the upper abdomen and after meals, which is where NIDDK places indigestion.

MedlinePlus, the medical encyclopedia of the U.S. National Library of Medicine, sorts abdominal pain by pattern in a way that helps tell this kind from the others.9

MedlinePlus adds a caution that applies to everything on this page: how bad the pain is does not always reflect how serious its cause is. Gas can hurt a great deal, and early appendicitis may cause only mild pain.9

The pain the labels warn about first: pancreatitis

All four labels carry a warning headed "Acute Pancreatitis". It says that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. It tells prescribers to watch for the signs, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. And it gives one instruction: if pancreatitis is suspected, discontinue the medicine.1,2,3,4

The patient leaflet that comes with each of the four medicines puts it in plain words, and addresses the patient directly. Stop using the medicine and call your health care provider right away if you have severe pain in your stomach area that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.1,2,3,4

NIDDK describes the pain of acute pancreatitis as pain that begins slowly or suddenly in the upper abdomen, sometimes spreads to the back, can be mild or severe, and may last for several days. Fever, nausea and vomiting, a fast heartbeat and a swollen or tender abdomen may come with it. People with acute pancreatitis usually look and feel seriously ill, NIDDK says, and need to see a doctor right away.5

How often it happened in the trials is in the labels, as cases confirmed by an independent review.

TrialsOn the drugComparison group
Wegovy, adult weight trials4 patients, 0.2 per 100 patient-years1 patient, less than 0.1
Zepbound, weight trials0.2% of patients, 0.14 per 100 years0.2%, 0.15
Ozempic, glycemic control trials7 patients, 0.3 per 100 patient-years3 patients, 0.2
Mounjaro, clinical studies13 patients, 0.23 per 100 years3 patients, 0.11

Prescribing information, section 6.1. The comparison group is placebo for Wegovy and Zepbound and comparator treatments for Ozempic and Mounjaro.1,2,3,4

These are small numbers: between 1.4 and 3 people of every 1,000 followed for a year on the drugs, and up to 2 in the comparison groups. Outside the trials the evidence is mixed. A U.S. claims study of people with obesity found pancreatitis recorded in 4.6 of every 1,000 semaglutide users a year and 7.9 of every 1,000 liraglutide users, against 1.0 on a comparison weight-loss drug, a hazard ratio of 9.09 with a wide interval from 1.25 to 66.00.10 A 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants concluded that GLP-1 medicines probably have little or no effect on the risk of pancreatitis.11

Pancreatitis is not rare in general. NIDDK counts about 275,000 hospital stays for acute pancreatitis in the United States each year, and names men, African Americans, and people with a family history of pancreatitis or a personal or family history of gallstones as more likely to get it.5

Whatever the true size of the risk, the practical rule does not depend on it. Gallstones are the most common cause of acute pancreatitis according to NIDDK, and heavy alcohol use is another.5 Persistent or severe pain in the upper abdomen, with or without vomiting, is a reason to be seen and not a reaction to wait out.

Gallbladder pain

The second warning is headed "Acute Gallbladder Disease". The Wegovy label says treatment is associated with an increased occurrence of gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis). It adds a sentence that answers the obvious objection: substantial or rapid weight loss can increase the risk of gallstones, but the incidence of acute gallbladder disease was greater on Wegovy than on placebo even after accounting for the degree of weight loss.1

MedicineGallstonesGallbladder inflammation
Wegovy injection, adults1.6% against 0.7% on placebo0.6% against 0.2%
Wegovy injection, ages 12 and older3.8% against 0%0.8% against 0%
Wegovy tablet2.5% against 1%Not given
Zepbound1.1% against 1%0.7% against 0.2%
Ozempic1.5% on 0.5 mg, 0.4% on 1 mg, none on placeboNot given
MounjaroAcute gallbladder disease of any kind: 0.6% against 0%

Prescribing information, sections 5 and 6.1.1,2,3,4

The pooled trials agree with the labels here. The same 2025 meta-analysis found that GLP-1 medicines increased the risk of gallstones, with a risk ratio of 1.46 and 2 more cases for every 1,000 people.11

The patient leaflets list four symptoms of gallbladder problems to report: pain in the upper stomach, fever, yellowing of the skin or eyes, and clay-colored stools. The Zepbound, Ozempic and Mounjaro leaflets say to tell your health care provider right away, and the Wegovy leaflet adds that some gallbladder problems need surgery.1,2,3,4

Gallstones are common with or without a GLP-1. NIDDK says they affect 10 to 15 percent of the U.S. population, almost 25 million people, and that about a quarter of the nearly 1 million people diagnosed each year will need treatment, usually surgery.6

NIDDK describes what a gallbladder attack feels like. It usually causes pain in the upper right abdomen, sometimes lasting several hours. Attacks often follow heavy meals and usually occur in the evening or during the night. Most people with gallstones have no symptoms at all, and gallstones that do not block the bile ducts do not cause symptoms.6 Its list of who is more likely to develop gallstones reads like a description of the people prescribed these medicines: people with obesity, especially women, people with diabetes and insulin resistance, and people who have had fast weight loss.6

The two warnings, in numbersFDA labels
Show

Pancreatitis is shown as cases per 1,000 people followed for a year, converted from the labels' rates per 100 patient-years. Gallstones and gallbladder inflammation are shown as the share of people in the trials. Grey bars are the comparison groups.

What the place of the pain suggests

The sources describe several of these pains by where they are felt. The guide below collects those descriptions. It cannot diagnose anything, and MedlinePlus's caution applies: mild pain can have a serious cause.9

Where is the pain?NIDDK, MedlinePlus
I feel it

    Each description is taken from the source named in it. Organs do not always follow the textbook, and the same condition can be felt in different places.

    Causes that have nothing to do with the injection

    With a placebo rate of 4% to 10%, much of the abdominal pain during treatment is not caused by the drug. Three causes deserve a mention because they must not be mistaken for a side effect.

    Appendicitis. NIDDK's description: pain that may begin near the belly button and move lower and to the right, start suddenly and even wake you from sleep, get worse when you move around, take deep breaths, cough or sneeze, and worsen in a matter of hours. Loss of appetite, nausea or vomiting, fever and swelling of the abdomen may follow. Its advice is to talk with a doctor right away.8 Loss of appetite and nausea are also what the medicine causes, which is why the character of the pain, and whether it is getting worse by the hour, matters more than the company it keeps.

    A blockage of the intestines. MedlinePlus says generalized pain that becomes more severe may be caused by a blockage, and its emergency list includes being unable to pass stool, especially with vomiting.9 Ileus and intestinal obstruction are on the labels of all four medicines as reactions reported after approval.1

    Constipation. It is common on these medicines, 24% on Wegovy in the label trials, and it causes cramping and bloating of its own.1 Our page on constipation on a GLP-1 covers it.

    How long is too long

    None of the labels reports how long an episode of abdominal pain lasted in the trials. The time limits come from general guidance, and they are short.

    My pain against the time limitsMedlinePlus

    The marks are for pain that is mild and not getting worse. Sudden, sharp or severe pain, or any of the signs in the last section, does not wait for a mark.

    What helps the ordinary kind

    For mild abdominal pain MedlinePlus suggests these home care steps:9

    To prevent some kinds of abdominal pain it adds: drink plenty of water each day, eat small meals more frequently, exercise regularly, and limit foods that produce gas.9

    The advisory written for people on GLP-1 therapy points the same way for this class of medicine. It notes that vomiting is more likely with large meals, that foods high in protein or fat can further slow the emptying of the stomach, and that alcohol may worsen nausea and reflux and should be minimized.12 Smaller meals with less fat at one sitting is the advice the two sources share.

    If pain follows every dose increase, the labels leave room to slow down. The Wegovy label says that if a patient does not tolerate a dose during escalation, the prescriber can consider delaying the next step for four weeks, and the Zepbound label allows a lower maintenance dose when one is not tolerated.1,2 Both are decisions for the prescriber.

    When to get help

    MedlinePlus says to get medical help right away, or call 911 or the local emergency number, if you:9

    NIDDK adds the signs of severe pancreatitis and of a complicated gallbladder attack, both for care right away: pain or tenderness in the abdomen that is severe or becomes worse, fever or chills, a fast heartbeat, shortness of breath, a yellowish color of the skin or the whites of the eyes, and tea-colored urine with light-colored stools.5,6

    Short of an emergency, MedlinePlus says to contact your provider about pain that does not improve in 24 to 48 hours, discomfort that lasts a week or longer, bloating for more than 2 days, a fever over 100掳F with the pain, a prolonged poor appetite, unexplained weight loss, or being unable to keep down any foods or liquids.9 A poor appetite and weight loss are the intended effects of these medicines, so on a GLP-1 those two are worth raising with the prescriber when they come together with pain.

    Pain, plus what?MedlinePlus, NIDDK
    Right now I have
    Or the pain is milder, but

    Log the pain with the day of each dose, and the pattern is ready for the appointment.

    Open the app

    The lists are from MedlinePlus and NIDDK and apply to abdominal pain from any cause. A page cannot examine you. If something feels seriously wrong, do not wait for it to agree.

    Short answers to common questions

    Is stomach pain normal on Ozempic?

    It is a common reaction: 7.3% on 0.5 mg and 5.7% on 1 mg in the label trials, against 4.6% on placebo.

    How common is it on Wegovy and Zepbound?

    20% on Wegovy 2.4 mg against 10% on placebo, and 9% to 10% on Zepbound against 5%.

    What does pancreatitis pain feel like?

    NIDDK describes pain in the upper abdomen that may spread to the back, begins slowly or suddenly, and may last for several days, often with nausea, vomiting or fever. The labels describe it as persistent or severe.

    How common is pancreatitis on these medicines?

    In the label trials it was confirmed in 1.4 to 3 people of every 1,000 followed for a year, against up to 2 in the comparison groups. A meta-analysis of 55 trials found probably little or no effect on the risk.

    Do GLP-1 medicines cause gallstones?

    The labels say they are associated with more gallbladder disease: on Wegovy, gallstones in 1.6% against 0.7% on placebo. Pooled trials found a risk ratio of 1.46.

    Where is gallbladder pain felt?

    Usually in the upper right abdomen, sometimes for several hours, often after a heavy meal and in the evening or at night.

    How long should I wait before calling?

    MedlinePlus says to contact your provider about pain that does not improve in 24 to 48 hours. Sudden, sharp or severe pain should not wait at all.

    Should I stop the medicine if my stomach hurts?

    For severe pain that will not go away, yes: the patient leaflets of all four medicines say to stop using the medicine and call your health care provider right away. For ordinary discomfort the labels allow a slower dose escalation instead, and that is a decision to make with the prescriber.

    How this page was built

    Every number was read in its source on November 20, 2026. The rates of abdominal pain, pancreatitis and gallbladder disease, and the instructions to patients, come from the current prescribing information and Medication Guides of the four medicines. The descriptions of each kind of pain come from NIDDK's pages on pancreatitis and gallstones (last reviewed November 2017), appendicitis (July 2021) and indigestion (March 2025). The patterns of pain, home care and the lists of when to get help come from the MedlinePlus entry on abdominal pain reviewed in January 2026. The observational figures come from the full text of a 2023 JAMA research letter, and the pooled trial results from the abstract of a 2025 meta-analysis.

    The limits are these. The labels bundle every kind of abdominal pain and discomfort into one row and do not report how long it lasted. No source here studied which pains on a GLP-1 turn out to be serious. The guide by location repeats general descriptions and cannot tell one cause from another in a particular person. This page does not suggest doses or advise stopping a medicine.

    Sources

    1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1, 6.2 and 17. accessdata.fda.gov
    2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1 and 17. accessdata.fda.gov
    3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6.1 and 17. accessdata.fda.gov
    4. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.1 and 17. accessdata.fda.gov
    5. National Institute of Diabetes and Digestive and Kidney Diseases. Pancreatitis: Definition and Facts; Symptoms and Causes. Last reviewed November 2017, read November 20, 2026. niddk.nih.gov
    6. National Institute of Diabetes and Digestive and Kidney Diseases. Gallstones: Definition and Facts; Symptoms and Causes. Last reviewed November 2017, read November 20, 2026. niddk.nih.gov
    7. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Indigestion. Last reviewed March 2025, read November 20, 2026. niddk.nih.gov
    8. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Appendicitis. Last reviewed July 2021, read November 20, 2026. niddk.nih.gov
    9. MedlinePlus Medical Encyclopedia. Abdominal pain. U.S. National Library of Medicine; reviewed January 13, 2026, read November 20, 2026. medlineplus.gov
    10. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 2023;330:1795-1797. doi:10.1001/jama.2023.19574
    11. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
    12. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336

    Related analyses

    Log each dose and each symptom, and bring the dates to your prescriber.

    Open Dose Insider